Insilico Medicine utilizes a generative AI platform to streamline drug discovery and development for cancer and age-related diseases, significantly reducing the time and cost associated with bringing new medications to market. The platform integrates multi-omics data analysis and machine learning to identify novel drug targets and predict clinical trial outcomes, enhancing the efficiency of pharmaceutical research.
Funding
Funding not disclosed
Founders
Product
Problem
The traditional drug discovery and development process for cancer and age-related diseases is lengthy and expensive, often failing to deliver effective treatments in a timely manner. Identifying promising drug targets and predicting clinical trial outcomes remains a significant challenge, hindering the efficiency of pharmaceutical research.
Solution
Insilico Medicine offers Pharma.AI, a commercially available end-to-end generative AI software and automation platform designed to improve the quality and productivity of pharmaceutical research. The platform integrates multi-omics data analysis and machine learning to accelerate target discovery, generate novel lead-like molecules, and predict clinical trial success. By leveraging AI, Pharma.AI aims to significantly reduce the time and cost associated with bringing life-saving medications to patients. The suite includes tools for disease modeling, target prioritization, de-novo drug design, and clinical trial outcome prediction.
Target Audience
The primary audience includes pharmaceutical companies, biotechnology firms, and research institutions involved in drug discovery and development for cancer and age-related diseases.
Features
- PandaOmics: Enables multi-omics target discovery and deep biology analysis.
- Chemistry42: Facilitates AI-driven de-novo drug design and scalable engineering of novel molecules.
- inClinico: Predicts clinical trial success rates and identifies weaknesses in trial design.
- Generative Biologics: Generates novel biologic drug candidates.
- Science42:DORA: Provides LLM assistants for scientific research.
- Flexible deployment options: Available as stand-alone technology or combined with Pharma.AI services for a data-driven AI-partnership.